(Press-News.org) SAN DIEGO (March 15, 2015) -- A novel therapy that would allow doctors to turn the body's blood-clotting ability off and on in a more controlled way was about as effective as established anticoagulants in patients undergoing angioplasty but was associated with higher rates of moderate to severe bleeding, according to an analysis of data from a terminated Phase III trial presented at the American College of Cardiology's 64th Annual Scientific Session. The study was officially halted in August due to an excess of severe allergic reactions, so authors caution that the data should be considered exploratory given the early termination.
Before the trial was stopped, 3,232 patients undergoing angioplasty, a procedure to open blocked coronary arteries, were enrolled in the study at 225 hospitals in 17 countries including North America and Europe. The study was designed to compare the safety and efficacy of the REG1 Anticoagulation System and bivalirudin--a commonly used anticoagulant--in a total of 13,200 patients. Patients were equally randomized to the bivalirudin or REG1 in an open-label fashion and data was collected at three and 30 days.
No differences were found between patients receiving REG1 compared to bivalirudin in terms of the study's primary efficacy endpoint--a composite of all-cause death, heart attack, stroke or urgent revascularization, which was reported in 6.7 percent of patients in the REG1 arm and 6.4 percent of patients receiving bivalirudin three days after angioplasty. Efficacy was still comparable at 30 days.
The REG1 system failed to show a benefit in the primary safety endpoint of bleeding compared to bivalirudin. Using a validated bleeding scale, patients receiving REG1 had a 0.4 percent rate of severe or fatal bleeding compared to 0.1 percent with patients who were given bivalirudin for anticoagulation. Moderate to severe bleeding was significantly higher in the REG1 group compared with bivalirudin.
Serious allergic reactions were seen in 10 out of 1,605 patients in the REG1 arm, one of which was fatal and the others were anaphylactic reactions. Only one patient in the bivalirudin group had a serious allergic event.
"This anticoagulant system is associated with infrequent but an unacceptably high rate of severe allergic reactions," said Roxana Mehran, M.D., director of Interventional Cardiovascular Research and Clinical Trials at Mount Sinai Heart at The Mount Sinai Hospital and professor of Medicine in Cardiology at Icahn School of Medicine at Mount Sinai, and one of the principal investigators of this trial. Research is ongoing to determine the exact cause of the allergic reactions, and Mehran said she hopes this does not deter the search for novel anticoagulants for use in this patient population.
When patients undergo angioplasty, they need medications to thin the blood to prevent clots from forming in the coronary artery, which can result in stroke, heart attack, repeat procedures or even death, but physicians must balance preventing blood clots with the risk of potentially dangerous bleeding.
"It's the Achilles' heel in cardiovascular medicine--how do we protect patients against any kind of blood clotting without exposing them to a higher risk of bleeding?" Mehran said. "We are constantly refining the antithrombotic therapies we use during PCI, and this seemed promising."
More than 1 million people in the United States undergo angioplasty each year. Roughly 0.6 to 4.8 percent of these people will die, 0.2 percent will suffer a stroke and up to 6 percent will suffer vascular complications in hospital. About 5.8 percent of people will also suffer bleeding related complications within 72 hours of angioplasty.
Mehran said the ideal anticoagulant is one that works fast, has a predictable dose and can efficiently stop clots from forming on top of catheters, but it can also be quickly reversed. Blood clotting in the body is regulated by a set of proteins in the blood, called coagulation factors, and platelets. The REG1 system uses a molecule called pegnivacogin that binds to the blood coagulation Factor IXa receptor to deactivate blood clotting, and anivamersen, an active control agent that rapidly reverses the anticoagulant effect to quickly help return blood clotting activity to normal.
"Within seconds of giving the reversal agent anticoagulation is nearly completely reversed because it looks for its friend and grabs it off the receptor immediately," Mehran said. "With a technique like this, we could provide blood thinning as needed and then take it away immediately after finishing angioplasty." But, she said, further improvements are needed in its safety profile.
Researchers started recruiting patients in September 2013. In April, because there were a handful of allergic reactions seen in the earlier Phase II trial, all of the safety endpoints for the first 1,000 patients were carefully reviewed by the Data Safety and Monitoring Board, Mehran said. But in June both the executive committee and the sponsor decided to suspend the trial, and upon adjudication of events, the trial was permanently halted in August. Patients who had a heart attack within 48 hours of angioplasty, had contraindications for anticoagulation, were at high risk of bleeding, or had an allergy or intolerance to aspirin or certain other inhibitors were excluded from the study.
INFORMATION:
This study was funded by Regado Biosciences Inc., the maker of the REG1 system. Mehran has served on the scientific advisory board for Regado Biosciences.
The ACC's Annual Scientific Session brings together cardiologists and cardiovascular specialists from around the world each year to share the newest discoveries in treatment and prevention. Follow @ACCMediaCenter and #ACC15 for the latest news from the meeting.
The American College of Cardiology is a 49,000-member medical society that is the professional home for the entire cardiovascular care team. The mission of the College is to transform cardiovascular care and to improve heart health. The ACC leads in the formation of health policy, standards and guidelines. The College operates national registries to measure and improve care, provides professional medical education, disseminates cardiovascular research and bestows credentials upon cardiovascular specialists who meet stringent qualifications. For more information, visit acc.org.
INFORMATION:
SAN DIEGO (March 15, 2015) -- Use of computed tomography coronary angiography, which provides 3-D images of the heart, coupled with standard care allows doctors to more accurately diagnose coronary artery disease in patients presenting with chest pain, therefore, leading to more appropriate follow-up testing and treatments, according to research presented at the American College of Cardiology's 64th Annual Scientific Session. Data also showed a trend toward a lower incidence of heart attacks among the group receiving the tests, known as CT scans, compared to usual care. ...
SAN DIEGO (March 15, 2015) -- Patients taking evolocumab--an investigational therapy previously shown to dramatically lower "bad" cholesterol--were half as likely to die, suffer a heart attack or stroke, be hospitalized or need a procedure to open blocked arteries compared with those who received standard care, according to research presented at the American College of Cardiology's 64th Annual Scientific Session in San Diego.
In this open-label study, the rate of cardiovascular events was 2.18 percent after one year in the standard of care group, most of whom were on ...
SAN DIEGO (March 15, 2015) -- The SAPIEN 3 heart valve demonstrated lower death, stroke and paravalvular leak rates than earlier generation devices in patients at high risk for surgery and showed encouraging results in intermediate-risk patients, according to research presented at the American College of Cardiology's 64th Annual Scientific Session.
Transcatheter aortic valve replacement, known as TAVR, is approved for patients with severe aortic stenosis--narrowing of the valve in the heart's main artery--whose health profile makes them ineligible or high-risk candidates ...
SAN DIEGO (March 15, 2015) -- An investigational device that deflects debris away from the brain during transcatheter aortic valve replacement seems to improve in-hospital safety outcomes and cognitive scores at discharge, according to preliminary findings from a small randomized study presented at the American College of Cardiology's 64th Annual Scientific Session.
The valve replacement procedure, known as TAVR, dislodges minute particles from the clogged valve, freeing them to float through the bloodstream. Much of this debris travels "downstream" from the heart, but ...
SAN DIEGO (March 15, 2015) -- Five-year data suggest that the SAPIEN transcatheter heart valve is a feasible option for patients with severe aortic stenosis deemed to be at high risk for open-heart surgery, though valve leakage was more common with the first-generation valve evaluated in this study than with surgery, according to research from PARTNER I presented at the American College of Cardiology's 64th Annual Scientific Session.
When the blockage of an aortic valve becomes severe, replacement is the only real treatment choice, but many elderly and frail people are ...
SAN DIEGO (March 15, 2015) -- Two-year data show a continued survival advantage for self-expanding transcatheter aortic valve replacement (TAVR) over standard surgery in high-risk patients with severe aortic stenosis, according to research presented at the American College of Cardiology's 64th Annual Scientific Session.
Aortic stenosis--a problem that occurs when the valve in the heart's main artery doesn't open fully--forces the heart to work harder to pump blood and is life-threatening over time. Valve replacement is common when this condition becomes severe, but the ...
SAN DIEGO (March 15, 2015) --The commercial track record with transcatheter mitral valve repair, approved for patients at high risk for surgery, compares favorably with pre-approval reports, according to findings from a U.S. registry presented at the American College of Cardiology's 64th Annual Scientific Session.
Healthy valves function as one-way gates that keep blood moving forward through the heart. Severely damaged mitral valves don't close properly, allowing blood to leak backward. If the valve isn't repaired or replaced, the condition can cause serious health ...
Police are ill-equipped to investigate non-criminal deaths and face a challenge to avoid re-traumatising bereaved families as well as emotionally protecting themselves, according to QUT research.
Investigating death: the emotional and cultural challenges for police found it was usually junior officers sent to sudden death investigations and tasked with not only gathering evidence, but also comforting family members and explaining the coronial process.
The research has been published in the journal of Policing and Society.
"The vast majority of deaths are neither ...
NEW YORK, NY - Researchers have built a new computational tool that identifies 800 different ways people are at increased risk for post-traumatic stress disorder (PTSD), permitting for the first time a personalized prediction guide.
Results from the study out of NYU Langone Medical Center are published online (date) in the journal BMC Psychiatry.
"Our study shows that high-risk individuals who have experienced a traumatic event can be identified less than two weeks after they are first seen in the emergency department," says Arieh Y. Shalev, MD, the Barbara Wilson ...
NEW YORK, March 15, 2015 - Most physicians are aware of the importance of lifestyle factors in preventing cardiovascular disease (CVD) -- and believe diet is as important as statin therapy and exercise, according to a new survey from NYU Langone Medical Center.
Researchers found that a majority of doctors would welcome additional training in diet and nutrition so that they can effectively inform patients on the subject. The study will be presented at the American College of Cardiology's 64th Annual Scientific Session as a poster presentation.
The 28-question online survey, ...
